PFM
BEAM icon

Privium Fund Management’s Beam Therapeutics BEAM Stock Holding History

Privium Fund Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.52M Sell
63,982
-7,518
-11% -$209K 0.32% 38
2025
Q4 		$1.98M Buy
71,500
+10,500
+17% +$268K 0.36% 32
2025
Q3 		$1.48M Buy
+61,000
New +$1.21M 0.27% 35

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Privium Fund Management's BEAM Position: Q1 2026 in Review

Privium Fund Management reduced its Beam Therapeutics (BEAM) stake by 11% in Q1 2026, selling an estimated $209K and leaving 63,982 shares worth $1.52M. The position accounts for 0.32% of the portfolio, ranked #38.

Privium Fund Management first reported a position in BEAM in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.98M in Q4 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Privium Fund Management held 63,982 shares of Beam Therapeutics worth $1.52M as of Q1 2026.
  • Privium Fund Management sold 7,518 Beam Therapeutics shares in Q1 2026, an estimated $209K.
  • Beam Therapeutics made up 0.32% of Privium Fund Management's portfolio in Q1 2026, its #38 holding.
  • Privium Fund Management first reported a position in Beam Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Privium Fund Management's Beam Therapeutics position peaked at $1.98M in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Privium Fund Management's 13F filing for Q1 2026, filed 5 May 2026.